People · Operator
Named in public records as an officer, director or promoter · active 2013–2026 · Other Technology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Taxon Biosciences Inc. | — | Other Technology | Series A | $4.0M | $111.3M | 2013 |
| Ayres Associates Inc. | — | Other | Pre-Seed | $3.7M | $1.9M | 2026 |
Matthew Ashby at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Ashby on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Kim | 1 | 10 |
| Paul Deutch | 1 | 4 |
| Meghan Sharp | 1 | 3 |
| Lisa Pronschinske | 1 | 1 |
| Bruce Ommen | 1 | 1 |
| Mark Faanes | 1 | 1 |
| Tami Satre | 1 | 1 |
| Richard Kirby, IV | 1 | 1 |
| Matt Ashby | 1 | 1 |
| Jason Ingram | 1 | 1 |
| Richard Kirby | 1 | 1 |
| Rick Kirby | 1 | 1 |
| Richard Schoenthaler | 1 | 1 |
| Karl Murch | 1 | 1 |
| Eric Sorensen | 1 | 1 |
| Karl Alan Murch | 1 | 1 |
| Jason Alan Ingram | 1 | 1 |
| Jan Alan Zander | 1 | 1 |
| Susan Alan Kirkpatrick | 1 | 1 |
| Rich Alan Schoenthaler | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.